SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-102850
Filing Date
2020-09-08
Accepted
2020-09-08 08:21:05
Documents
16
Period of Report
2020-09-04
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2029742-2_8k.htm   iXBRL 8-K 31501
2 EXHIBIT 3.1 tm2029742d2_ex3-1.htm EX-3.1 6871
3 EXHIBIT 3.2 tm2029742d2_ex3-2.htm EX-3.2 159991
4 EXHIBIT 99.1 tm2029742d2_ex99-1.htm EX-99.1 14113
8 GRAPHIC tm2029742d2_ex99-1img001.jpg GRAPHIC 11160
  Complete submission text file 0001104659-20-102850.txt   448120

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA mnlo-20200511.xsd EX-101.SCH 3213
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mnlo-20200511_lab.xml EX-101.LAB 34591
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mnlo-20200511_pre.xml EX-101.PRE 22728
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2029742-2_8k_htm.xml XML 3825
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 201163052
SIC: 2834 Pharmaceutical Preparations